Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Regeneron

Regeneron Hits A New Record High On The Approval That 'Could Not Come Soon Enough'

Shares of REGN stock jumped Monday after the FDA approved Regeneron Pharmaceuticals' high-dose Eylea following a delay this summer.

Investors Business Daily

The Unexpectedly Good News That Helped Regeneron Retake Its 200-Day Line

Regeneron guided to a faster-than-expected approval timeline for a high dose of its eye drug Eylea on Thursday, and REGN stock jumped.

Investors Business Daily

Regeneron Stock Crumbles After FDA Rejects Its Next Blockbuster Contender

The Food and Drug Administration rejected a high-dose version of Regeneron's eye drug Eylea on Tuesday, leading REGN stock to crumble.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

A more aggressive FTC is starting to target drug mergers and industry middlemen

Under the leadership of an aggressive opponent of anti-competitive business practices, the Federal Trade Commission is moving against drug companies and industry middlemen as part of the Biden administration’s push for lower drug prices at the pharmacy counter.

Tribune News Service

Regeneron Sacrifices A Breakout As Competition Hammers At Its Biggest Moneymaker

The struggles continued for Regeneron's blockbuster eye disease treatment, Eylea, in the first quarter — leading REGN stock to dive Thursday.

Investors Business Daily

Dow Jones Futures Fall As PacWest Dives On Sale Report; Apple Earnings On Tap

PacWest Bancorp plunged on a sale report, slamming other bank stocks. Apple headlines big earnings Thursday.

Investors Business Daily

Dow Jones Futures Rise: Big News For Merck; Tesla, Apple Lead 7 Stocks Near Buy Points

Tesla and Netflix are near buy points with earnings due in a volatile market rally. Apple and Lululemon have tight entries.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Medicare Negotiation Undercuts Biotech Stocks Regeneron, Halozyme

Confusion over new Centers for Medicare and Medicaid Services negotiating plans sent REGN and HALO stocks tumbling Thursday.

Investors Business Daily

Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review

The market rally had powerful gains on a relatively tame Federal Reserve and a booming Meta stock, shrugging off many weak earnings reports.

Investors Business Daily

Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples

Regeneron Pharma beat quarterly forecasts Friday, but its partner Sanofi posted a mixed report. Regeneron stock rose as SNY stock toppled.

Investors Business Daily

Biotech Giant Regeneron Hit As Eylea Gives Ground To Avastin

Regeneron Pharmaceuticals said sales of its linchpin Eylea drug have been negatively impacted by a short-term shift to rival drug Avastin.

Investors Business Daily

Dexcom Leads 5 Stocks Near Buy Points

Dexcom and other top stocks to watch this week combine strong technicals with generally solid fundamentals.

Investors Business Daily

What was the longest-running Covid infection and how were they cured?

A British man tested positive for Covid for more than two years and survived - but many more have Long Covid

Evening Standard

Regeneron, Bayer offer more promising data for aging eye drug

Bayer AG and Regeneron Pharmaceuticals Inc.’s blockbuster eye drug reached another clinical milestone by showing sustained efficacy in trials that could help the companies push back against a competing product from Roche Holding AG.

Tribune News Service

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Top Funds Focus Their Cash On These Three Sectors

The best mutual funds are scooping up medical, financial and energy names. But they have their eyes on these other sectors.

Investors Business Daily

Regeneron Sinks Despite Massive Earnings Beat On A Notable Blockbuster Miss

Regeneron Pharma topped third-quarter expectations Thursday, reporting less of a decline than expected. But REGN stock was down early.

Investors Business Daily

CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?

Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments.

The Denver Post

A Colorado teen’s long COVID isn’t just persisting — after 2 years, it’s getting worse

DENVER -- Reminders of life outside Lilly Downs’ Denver hospital room dotted the walls.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Regeneron Stock Soars On Pair Of Successful Trials

Studies "support aflibercept 8 mg as a potential new standard-of-care," Regeneron Pharmaceuticals said. Regeneron stock leapt in huge volume.

Benzinga

Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know

After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.

Investors Business Daily

Regeneron Soars As Eylea Outplays Competition, Both Beating Forecasts And Growing

Regeneron Pharmaceuticals outplayed its competition in eye diseases Wednesday, reporting Eylea sales that beat, leading REGN stock to soar.

The Independent UK

How Donald Trump’s fight with Covid unfolded two years before Biden diagnosis

Low blood oxygen levels and lung issues led officials to believe Trump might have to be put on ventilator in 2020

Investors Business Daily

Could The Next CRISPR From Verve, Beam Signal The End To High Cholesterol?

Verve Therapeutics said Tuesday it edited the genes of someone with high cholesterol. The first-ever move could push VERV stock higher.

Investors Business Daily

Biotechs Say ESG Is Core To Their Mission; Do Investors Believe Them?

The biotech industry is trying to catch the ESG investing bug. But that doesn't mean investors are giving it credit, executives say.

Benzinga

Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates

The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations